Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders... Show more
A.I.dvisor indicates that over the last year, OMER has been loosely correlated with GNPX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if OMER jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To OMER | 1D Price Change % | ||
|---|---|---|---|---|
| OMER | 100% | -1.01% | ||
| GNPX - OMER | 51% Loosely correlated | -1.10% | ||
| EVAX - OMER | 42% Loosely correlated | -2.28% | ||
| VCYT - OMER | 40% Loosely correlated | -2.68% | ||
| SANA - OMER | 38% Loosely correlated | -6.09% | ||
| INM - OMER | 36% Loosely correlated | N/A | ||
More | ||||
a developer of pharmaceutical products
Industry Biotechnology
On October 09, 2026, the Stochastic Oscillator for OMER moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 51 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 86%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on OMER as a result. In 75 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +5.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 222 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The 10-day RSI Indicator for OMER moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 29 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for OMER turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
OMER broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.831) is normal, around the industry mean (26.823). P/E Ratio (11.764) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OMER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.